Skip to content
  • Sunday, 26 July 2026
  • 2:49 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • FDA refuses to review Moderna’s mRNA flu vaccine
Laboratory Automation & Robotics

FDA refuses to review Moderna’s mRNA flu vaccine

Lana Keisha Mar 21, 2026 0

Moderna, a leading biotechnology company known for its pioneering work in mRNA technology, has been dealt a significant setback by…

Read More
Laboratory Automation & Robotics

FDA reverses course, agrees to review Moderna’s mRNA flu vaccine

Lana Keisha Mar 20, 2026 0

The U.S. Food and Drug Administration (FDA) has officially reversed its earlier stance, agreeing to review Moderna’s messenger RNA (mRNA)…

Read More

Posts pagination

1 2
Deloitte report showed pharma returns rising to 7%. GLP-1s did most of the work.Humans Still Have Crucial Roles to Play in Medicine, Experts Emphasize Amidst AI AdvancementsMidlife Vitamin D Levels Linked to Lower Alzheimer’s Tau Biomarker; Study Signals Implications for Clinical LabsLong-Term Residential Exposure to Chlorpyrifos Increases Parkinson’s Disease Risk by Over Two and a Half Times UCLA Health Study Finds
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ